Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)
12 juin 2023 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare,...
Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
08 juin 2023 01h15 HE
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
02 juin 2023 08h00 HE
|
Novartis Pharma AG
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of...
Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
01 juin 2023 01h15 HE
|
Novartis Pharma AG
Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent...
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
25 mai 2023 01h15 HE
|
Novartis Pharma AG
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for...
New Sandoz Board of Directors appointed
15 mai 2023 01h15 HE
|
Novartis Pharma AG
Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2...
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
11 mai 2023 12h15 HE
|
Novartis Pharma AG
Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III...
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
09 mai 2023 15h00 HE
|
Novartis Pharma AG
Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform...
Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
04 mai 2023 01h15 HE
|
Novartis Pharma AG
Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six...
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
26 avr. 2023 12h42 HE
|
Novartis Pharma AG
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase...